The article explores the dual-edged nature of diabetes management technology, such as insulin pumps and continuous glucose monitors (CGMs), which have revolutionised care for type 1 diabetes patients but also pose significant risks.Tye Cummins nearly died after an Omnipod insulin pump delivered excessive insulin during sleep, highlighting the potential dangers of these devices.

While evidence shows CGMs and pumps improve blood-sugar control and reduce complications, adverse event reports have surged, with diabetes devices ranking among the top 10 in TGA records.Concerns include accuracy issues, alarm failures, and connectivity problems with smartphones.

Regulatory bodies like the TGA and US FDA face criticism for not adequately warning users about risks like Bluetooth interference with alarms, as seen in a fatal car crash linked to a CGM failure.Manufacturers defend their products, citing clinical evidence, but users report inaccuracies and safety concerns.

The article underscores the tension between technological advancement and the need for robust safety measures, with calls for stricter regulations and transparency.